Request for membership to create or review content for BOPA Digital SACT passport (Update)

Dear Member,

Regarding the earlier communication for registering to become a creator/reviewer of mock prescriptions:

This process has been amended and creation/review is open to free associates and above, as opposed to paid members only.

We apologise for any confusion.

How do you contribute?

We request that you register interest to be a creator and/or reviewer of Mock Prescriptions via the following link:

https://www.bopa.org.uk/mock-rx-creator-reviewer-registration/

You can also register within the BOPA SACT Verification Hub in the Contribution to Content tile.

Our mock prescription team will be in touch and will allocate you the required mock prescription content based on your indicated role, level of verification and speciality, and will advise from there.
This is to prevent duplication of entries.

We greatly appreciate any and all contributions to the ongoing use and success of the Passport and encourage all members to get involved in the creation of content.

Please see the relevant supportive SOPs for this process which are saved within the SOP tile of the BOPA SACT Verification Hub.

If you have any queries about this process, please get it touch via email ([email protected])

Kind Regards,

BOPA Passport Pillar

 

Please appreciate these are for UK-wide use and are not unique to any one nation, Trust or cancer centre. Content may not reflect your local practice.

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article